✦ LIBER ✦

566 Pharmacokinetics and pharmacodynamics of induction doses of peginterferon alpha-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in HCV genotype 1 patients who failed to respond to interferon/ribavirin

✍ Scribed by M. Diago; M. Romero-Gomez; J. Crespo; A. Olveira; R. Perez; R. Barcena; J.M. Sanchez-Tapias; M. Munoz-Sanchez

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1207 High-dose peginterferon alfa-2A (40

✍ DIAGO, M; ROMEROGOMEZ, M; DEVALME, H; CRESPO, J; VALDECILLA, H; OLVEIRA, A; LAPA 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

11 Efficacy of standard-dose and fixed-d

✍ P. Marcellin; G. Teuber; V. Canva; O. Weiland; A. Di Bisceglie; C. Brandao-Mello 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 127 KB

P.259 Retreatment with peginterferon alp

✍ P. Marcellin; G. Teuber; B. Freilich; O. Weiland; A. Di Bisceglie; C. Brandao-Me 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 119 KB

616 Population pharmacokinetic analysis

✍ J.R. Wade; E. Snoeck; M. Lamb; E. Duffe; K. Jorga 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 109 KB

187 Efficacy and safety of 22 weeks of m

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

328 Comparison of 48 or 72 weeks of trea

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB